Advertisement

Breast Cancer Research and Treatment

, Volume 122, Issue 1, pp 9–10 | Cite as

Overall survival in metastatic breast cancer: always our quest but not necessarily a primary endpoint

  • Nicholas J. Robert
Invited Commentary

Valachis et al. in their article “Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials” address an important development in breast cancer management. The use of bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor (VEGF), in combination with chemotherapy has been approved for first line therapy of metastatic breast cancer. This approval was the basis of an improvement of Progression Free Survival (PFS) in patients who received weekly paclitaxel plus bevacizumab compared to paclitaxel alone [1]. This was an open label protocol. Subsequently, there have been two additional first line studies, both with a placebo arm, and both showing an improvement in PFS [2, 3] In one study, in addition to taxanes, there were other common chemotherapy agents used in breast cancer (anthracycline containing combination and capecitabine) and they also showed an improvement in PFS. All three studies had Overall survival (OS) as a secondary...

Keywords

Breast Cancer Overall Survival Paclitaxel Bevacizumab Trastuzumab 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Miller K, Wand D, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NA (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Eng J Med 357:2666–2676CrossRefGoogle Scholar
  2. 2.
    Pivot X, Verma S, Thomssen C, Passos-Coelho JL, Latini L, Ciruelos R, Silva M, von Moss R, Chang H, Miles DW (2009) Clinical benefit of bevacizumab plus first-line docetaxel in elderly patients with locally recurrent or metastatic breast cancer. J Clin Oncol 27:15s (abstract 1094)CrossRefGoogle Scholar
  3. 3.
    Robert NJ, Dieras V, Glaspy J, Brufsky A, Bondarenko I, Lipatov Om Perez E, Yardley E, Zhou X, Phan S (2009) RIBBON-1: randomized, double blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer. J Clin Oncol 27:15s (abstract 1005)CrossRefGoogle Scholar
  4. 4.
    Saad ED, Katz A, Hoff PM, Buyse M (2010) Progression-free survival as surrogate and as true end point: insights from breast and colorectal cancer literature. Ann Oncol 21:7–12CrossRefPubMedGoogle Scholar
  5. 5.
    Slamon DJ, Leyland-Jones ShakS, Fuchs H, Patton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over expresses HER2. N Engl J Med 344:783–792CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  1. 1.Fairfax Northern VA Fairfax USA

Personalised recommendations